To determine whether the expression of TP53TG1 is induced by sorafenib treatment, the HCC cell lines HepG2, PLC/PRF/5, and Hep3B were incubated with various concentrations of sorafenib (0, 5, and 10 μM) for 48 h (Figure 1A). This evidence concerns the gene TP53TG1 and hepatocellular carcinoma.